Response to McGirr et al.'s Comment on "Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada"

Affiliations

• ¹ RTI Health Solutions, Research Triangle Park, NC, USA. mwilson@rti.org.
• ² Pfizer Inc., New York, NY, USA.
• ³ Departments of Pediatrics, Microbiology, Immunology, and Infectious Diseases, Faculty of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada.
• ⁴ Department of Pharmacy, University of Groningen, Groningen, The Netherlands.
• ⁵ Research Institute of Science in Healthy Aging and healthcaRE (SHARE), University of Groningen, University Medical Center Groningen (UMCG), Groningen, The Netherlands.
• ⁶ Pfizer Canada Inc., Kirkland, QC, Canada.
• ⁷ RTI Health Solutions, Research Triangle Park, NC, USA.
• ⁸ Pfizer Inc., Collegeville, PA, USA.